Chinese herbal granules for early-stage IgA nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a Chinese herbal medicine called Shenqi Yishen granules to see if it helps people with IgA nephropathy, a kidney disease. It aims to reduce protein in the urine and slow down kidney damage, and is for those who haven't needed dialysis yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with IgA nephropathy, a type of kidney disease, and be in an early stage (stage 1 or 2) of chronic kidney disease.
- Your urine should contain more than 0.3 grams of protein over 24 hours.
- You must be between 18 and 75 years old, of any gender.
- Your blood pressure, infections, and other health issues must be well managed.
- You should not have recently taken steroids, immunosuppressants, or certain pain relievers, and must not have used them in the past 3 months.
- You must be willing and able to follow the study plan and give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
This study continues treatment with an experimental medicine called HSK39297 for people with IgA nephropathy, a condition where the immune system damages the kidneys. The trial will track how safe and effective the medicine is over time in people who already completed an earlier study.
This trial tests a new medication for IgA nephropathy, a kidney disease that causes inflammation and protein loss in urine. It aims to see if the drug can safely slow down kidney damage and protect kidney function.
This trial tests an experimental drug (SC0062 capsule) for people with IgA nephropathy who have protein in their urine. It aims to see if the drug can help reduce kidney damage when added to standard treatments like blood pressure medications.
This trial tests a new drug, SHR-2173, for people with IgA nephropathy who still have a lot of protein in their urine despite standard care. The goal is to see if it can help protect kidney function.
This study tests a new medicine called CM313 for people with IgA nephropathy, a kidney disease. The goal is to see if it can help reduce protein in the urine and protect kidney function.
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.